Dnae Group Holdings

Point-of-need semiconductor DNA sequencing diagnostics for infection testing in hospital settings, developed in London

London, United KingdomFounded 2003dnae.com Website technologies

Highlights

New on EvolcAdded 2026-10-28

About Dnae Group Holdings

DNAe develops the LiDia-SEQ platform, a direct-from-specimen diagnostic system that performs DNA sequencing on a microchip for rapid, near-patient clinical results. The initial application focus is infectious disease diagnostics, including a bloodstream infection and antimicrobial resistance (BSI/AMR) test run on whole blood specimens. The company's products are labelled for research use only and are not yet for use in diagnostic procedures.

The company is developing its platform for hospital and point-of-need clinical settings, with targeted tests ranging from infectious diseases to cancer monitoring. Development is partly funded under a US Biomedical Advanced Research and Development Authority (BARDA) contract awarded in September 2016, reported as worth up to $51.9M. The company was founded in 2003 by Professor Christofer Toumazou as a spin-out from Imperial College London, and is headquartered in London, with operations in Washington, DC and a clinical diagnostic development site in San Diego, CA.

The company lists current vacancies in the United Kingdom and the United States. Its senior team includes CEO Sam Reed.

Product: LiDia-SEQ semiconductor sequencing system and BSI/AMR diagnostic test, for research use only

Jobs at Dnae Group Holdings

No open positions listed right now.

Leadership

Christofer Toumazou · Professor Christofer Toumazou
Source: company website

More biotech & pharma companies

Draig Therapeutics
Develops neuropsychiatric drug therapies for patients with depression and other brain disorders
Cardiff, United KingdomBiotech & pharmaFounded 2021
New on Evolc
Duke Street Bio
Develops cancer therapies targeting DNA damage repair deficiencies for patients with cancer
London, United KingdomBiotech & pharmaFounded 2020
New on Evolc
Elasmogen
Biopharma developing ELN28, a dual-acting TNFα and JAK inhibitor conjugate for hidradenitis suppurativa patients
Foresterhill, United KingdomBiotech & pharmaFounded 2014
New on Evolc
Eleventx
Extended-release RNA medicines for chronic disease, starting in cardiometabolic, developed with pharma partners
Cambridge, United KingdomBiotech & pharma2 open jobs
Enara Bio
Cancer immunotherapies for patients with solid tumors, developed using dark-antigen discovery and T-cell engager platforms
Oxford, United KingdomBiotech & pharmaFounded 2016
New on Evolc
Ensocell
AI-driven discovery of precision therapies for fibrotic and autoimmune diseases using human biological data
United KingdomBiotech & pharma1 open job
New on Evolc